Big effect
In 90 chronic hepatitis B patients, adding glutathione to standard antiviral therapy dropped ALT from ~349 to 31 U/L in three months — the control group only reached ~57 U/L.
This is an unusually large improvement in a key liver enzyme, but the finding comes from a single, moderately-sized clinical trial in a specific patient group, so it doesn't yet tell us whether healthy people or those with milder liver issues would see anything similar.
Glutathione, given alongside a standard hepatitis B drug, helped normalize a marker of liver injury (ALT) far more than the drug alone over 12 weeks. The study also reported improvements in other liver measures and viral clearance, though mild side effects like nausea and headache occurred. Because this is one of the first trials on this combination, the results are promising but not yet generalizable beyond chronic hepatitis B patients.
Where this fits in the evidence
This is among the first studies we've indexed on Glutathione for Improved Alanine Aminotransferase Level — treat it as an early signal until more research accumulates.
The study
- Randomized Controlled Trial (RCT)
- n = 90
- 2025-02-07
- BMC gastroenterology
This is a plain-language summary of a research finding, not medical advice. Pillser surfaces research signals to help you decide what's worth investigating — always consult a qualified professional before changing what you take.